Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on May 27, 2015. The filing serves as a report of a Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The document primarily reports on the results of the company's Annual General Meeting.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance events rather than financial performance data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this specific filing. The content is limited to the outcomes of shareholder voting.
Guidance, Outlook, and Risks
The filing includes a news release and a report of voting results regarding the Annual General Meeting. It does not contain management commentary on future guidance, outlook, specific risks, contingencies, or unusual items.
Key Facts for Investors
- The filing documents the results of the Annual General Meeting held by Aurinia Pharmaceuticals Inc.
- Exhibit 99.1 contains the news release regarding the meeting results.
- Exhibit 99.2 contains the detailed report of voting results.
- The report was signed by Michael R. Martin, Chief Operating Officer.
- No financial performance data is included in this specific Form 6-K.